TNF and Menkes disease: This study is encouraging, in particular because treatment-resistant patients with MD represent a negative selection for treatment outcome, and it indicates that CRP—the most widespread clinical marker for inflammation—may be a biomarker of anti-TNF-a antibody treatment outcome.